PING-ING LEEChiu C.-H.Chen P.-Y.CHIN-YUN LEELin T.-Y.FRANK LEIGH LULI-MIN HUANGWU-SHIUN HSIEHTang R.-B.Soong W.-J.Wang C.-C.Huang F.-Y.Lien R.-I.Huang Y.-C.Wong K.-S.Liu C.-C.Hwang K.-P.Lin Y.-Z.2021-01-072021-01-0720071608-8115https://www.scopus.com/inward/record.uri?eid=2-s2.0-37549057043&partnerID=40&md5=94cd66f50cde67ae72c486ca186408cbhttps://scholars.lib.ntu.edu.tw/handle/123456789/539597[SDGs]SDG3amoxicillin; amoxicillin plus clavulanic acid; ampicillin; antibiotic agent; azithromycin; C reactive protein; cefazolin; cefepime; cefotaxime; ceftazidime; ceftriaxone; cefuroxime; clarithromycin; erythromycin; imipenem; meropenem; oxacillin; penicillin G; piperacillin plus tazobactam; tetracycline; timentin; bacterial pneumonia; clinical feature; community acquired pneumonia; dose time effect relation; drug efficacy; drug tolerability; fluid therapy; hospitalization; human; Influenza virus; laboratory test; lung biopsy; lung lavage; Mycobacterium tuberculosis; oxygen therapy; practice guideline; recommended drug dose; review; thorax radiography; treatment duration; virus infection; Anti-Bacterial Agents; Child; Community-Acquired Infections; Humans; Pneumonia, Bacterial; Practice Guidelines as Topicreview182655362-s2.0-37549057043